- March 21, 2018
8:00 PM - 8:00 PM ET
On February 26, 2018, the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC) and American Society for Microbiology (ASM), along with other endoscope culturing experts announced the availability of voluntary, standardized protocols that were developed for duodenoscope surveillance sampling and culturing. Hospitals and health care facilities that utilize duodenoscopes can, in addition to meticulously following manufacturer reprocessing instructions, take these additional steps to further reduce the risk of infection and increase the safety of these medical devices. These protocols are an update to the Interim Duodenoscope Surveillance Protocol released by CDC in March 2015.
Duodenoscopes are flexible, lighted tubes that are used to treat patients undergoing endoscopic retrograde cholangiopancreatography (ECRP). These procedures often are life-saving and are the least invasive way of draining fluids from pancreatic and biliary ducts blocked by cancerous tumors, gallstones or other conditions. More than 500,000 ERCPs are performed each year in the United States. Duodenoscopes undergo a multi-step cleaning and high-level disinfection procedure called reprocessing so that they can be reused between patients. However, the complex design of duodenoscopes makes it difficult to remove contaminants compared to other types of endoscopes. If not thoroughly cleaned and disinfected, tissue or fluid from one patient can remain in a duodenoscope when it is used on a subsequent patient. In rare cases, this can lead to patient-to-patient infection.
Microbiological sampling and culturing of duodenoscopes involves sampling duodenoscope channels as well as the distal end of the endoscope and then culturing those samples with the goal of detecting bacterial contamination that may be present on the duodenoscope after reprocessing.
On March 22, 2018, the FDA, CDC, ASM and other endoscope culturing experts will review the voluntary duodenoscope surveillance sampling and culturing protocols, which can be leveraged by facilities to help monitor the quality of their reprocessing procedures. During the webinar, participants will also have an opportunity to ask questions about these voluntary protocols. No registration is required to participate in the webinar.
We appreciate your feedback on our webinar program. Following the webinar, we will provide a link to a short survey about your FDA CDRH webinar experience, which should take no more than 5-10 minutes to complete. Your responses are confidential and will be used to help ensure the quality of our webinar program.
NOTE: The FDA does not provide Continuing Education (CEU) or Certificates of Attendance for webinar attendance.
Target Audience: Health Care Facilities
If you have any questions, please contact the Division of Industry and Consumer Education (DICE) in the Center for Devices and Radiological Health (CDRH) at 1-800-638-2014, 301-796-7100 or email@example.com